AI and Biomarker Advancements Transforming Companion Diagnostic Tests in Oncology According to a newly published market research report by 24LifeSciences, global companion diagnostic tests in oncology market was valued at USD 4.37 billion in 2024 and is projected to reach USD 8.54 billion by 2032, growing at a compound annual growth rate (CAGR) of 10.3% during the forecast period 2025–2032. Companion diagnostic tests in oncology are in vitro medical devices that provide essential information for the safe and effective use of a corresponding therapeutic product. These tests are crucial for identifying specific biomarkers, such as genetic mutations or protein expressions, which determine a patient's eligibility for targeted cancer therapy. This personalized approach ensures treatments are administered only to patients most likely to benefit, thereby improving clinical outcomes and optimizing healthcare resource allocation. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/945 companion-diagnostic-tests-in-oncology-market